Tregzi is the second cell therapy to be approved by the FDA for use in the context of managing GVHD in HSCT patients, albeit ...

As the US relaxes an export ban on Anthropic's advanced AI tools, the company formally launched Claude Science, an AI ...

When it comes to global pharma pricing and market access, this moment is one of unprecedented change. As policy initiatives like Most Favoured Nations (MFN) and the EU’s Joint Clinical Assessment ...

In its second acquisition of the week, Ipsen will take control of Memo Therapeutics and a first-in-class drug for BK ...

Women with polyendocrine metabolic ovarian syndrome (PMOS) in the UK should get diagnosed sooner and be offered an annual review of their condition, according to new guidance from NICE. Draft guidance ...

Patients with newly diagnosed mantle cell lymphoma (MCL) could avoid chemotherapy with a regimen based on BeOne Medicines' ...

Sanofi is preparing to expand the use of its Pompe therapy Nexviazyme, currently approved only for late-onset cases of the ...

Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder (SAD), cratering ...

French pharma company Ipsen has agreed to buy cancer biotech Kartos Therapeutics of the US for $450 million upfront, gaining ...

Eli Lilly, Regeneron, and five other companies have been selected to take part in the FDA's PreCheck pilot programme, designed to make it easier and quicker to set up US manufacturing facilities. The ...

In a second M&A announcement today, Zymeworks has reached an agreement to buy Theravance Biopharma, claiming rights to ...

Viridian Therapeutics has fired a shot across Amgen's bows with FDA approval of Lumvoa, the first direct rival to Amgen's ...